Homocysteine and Cardiovascular Risk: The FM Practitioner's Guide

Homocysteine has one of the clearest dose-response relationships in cardiovascular medicine. For every 3-4 μmol/L increase in plasma homocysteine, cardiovascular risk rises by roughly 10-15%. Total homocysteine above 15 μmol/L roughly doubles stroke risk. Above 20, it's triple.

Despite this, most conventional cardiovascular workups don't include it.

For functional medicine practitioners, homocysteine is a standard component of any cardiovascular, cognitive aging, or methylation workup — because it's both a powerful risk marker and a direct readout of methylation pathway function.

---

What Is Homocysteine?

Homocysteine is a sulfur-containing amino acid produced as a byproduct of methionine metabolism. It doesn't come from diet directly — you don't eat homocysteine. You make it when you metabolize methionine (found in meat, eggs, dairy).

Under normal circumstances, the body rapidly converts homocysteine via one of two pathways:

1. Remethylation: Homocysteine is converted back to methionine using 5-methyltetrahydrofolate (the active form of folate) and vitamin B12 as cofactors. The enzyme is MTHFR-catalyzed methylenetetrahydrofolate reductase.

2. Transsulfuration: Homocysteine is converted to cysteine (then taurine and glutathione) using pyridoxal-5-phosphate (active B6) as a cofactor. This requires the CBS enzyme.

When either pathway is impaired — by nutrient deficiencies, genetic variants, or enzyme dysfunction — homocysteine accumulates.

Elevated homocysteine is toxic to the vascular endothelium. It:

• Oxidizes LDL cholesterol, making it more atherogenic
• Damages the endothelial glycocalyx (the arterial protective layer)
• Promotes platelet aggregation and thrombosis
• Drives inflammation via oxidative stress
• Impairs nitric oxide production, reducing arterial flexibility

---

Optimal vs. Conventional Reference Ranges

Conventional lab range: 5–15 μmol/L
Functional medicine optimal: <7 μmol/L
**Concerning:** >10 μmol/L
High risk: >15 μmol/L
Very high risk (hyperhomocysteinemia): >20 μmol/L

The conventional reference range includes most of the population — but cardiovascular research consistently shows that risk begins rising well before 15. A patient with homocysteine of 12 is technically "normal" by lab reference ranges and at meaningfully elevated cardiovascular risk by the research literature.

Functional medicine targets <7 μmol/L for cardiovascular and cognitive risk optimization.

---

Interpreting Elevated Homocysteine

When you see elevated homocysteine, the clinical question is: which pathway is impaired and why?

Pathway 1: Remethylation Failure

Clues: Elevated homocysteine + low B12 + low/normal folate + possible MTHFR variant

The most common driver of elevated homocysteine in your patient population. The remethylation pathway requires:

• 5-MTHF (methylfolate) — the active form of folate; dietary folate must be converted through a 4-step enzymatic process, the last step catalyzed by MTHFR
• Methylcobalamin (methyl-B12) — the cofactor for methionine synthase; cyanocobalamin (the cheap form in most supplements) requires additional conversion steps that many patients handle poorly
• Riboflavin (B2) — MTHFR stability depends on riboflavin; B2 deficiency impairs MTHFR function even in patients without genetic variants

MTHFR variants: The C677T polymorphism (present in ~10-15% of the population as homozygous TT) reduces MTHFR enzyme activity by up to 70%. These patients process dietary folate and folic acid poorly, making active 5-MTHF supplementation essential rather than optional.

Pathway 2: Transsulfuration Failure

Clues: Elevated homocysteine + low B6 (P5P) + low cysteine/taurine on OAT or amino acid panel + poor glutathione status

The transsulfuration pathway converts homocysteine to cysteine and downstream to glutathione and taurine. This requires:

• Pyridoxal-5-phosphate (P5P) — the active form of B6; many patients have poor conversion from pyridoxine (the common supplemental form)
• CBS enzyme function — Cystathionine beta-synthase; certain variants can reduce flux through this pathway

When transsulfuration is impaired, patients don't just accumulate homocysteine — they also have reduced glutathione production, increasing oxidative stress throughout the body.

Pathway 3: Renal Clearance

Clues: Elevated homocysteine + kidney disease markers + normal B12/folate/B6

The kidneys play a significant role in homocysteine clearance. Even mild reductions in GFR (eGFR 60-90) can contribute to homocysteine elevation. This is why homocysteine is often elevated in metabolic syndrome — renal hyperfiltration and early nephropathy impair clearance.

Contributing Factors (Regardless of Pathway)

Factor	Effect
Hypothyroidism	Reduces renal clearance of homocysteine
Aging	Progressive reduction in folate/B12 absorption and MTHFR activity
Smoking	Depletes B6 and B12; increases homocysteine ~2-4 μmol/L
Alcohol	Depletes B12 and folate; impairs methylation
Metformin	Blocks B12 absorption (ileal transport); check B12 in all metformin patients
PPIs	Impair B12 absorption (requires acidic environment)
Cholestyramine	Impairs folate absorption
Oral contraceptives	Deplete B6, B12, folate
Chronic inflammation	Impairs methylation cycle directly

---

The MTHFR Connection

MTHFR variants are among the most common genetic findings in functional medicine. The C677T variant in particular is directly relevant to homocysteine management.

Key clinical point: MTHFR variants don't cause elevated homocysteine in isolation — they increase vulnerability when combined with dietary insufficiency, high methionine load, or other stressors. Many homozygous C677T patients maintain normal homocysteine on adequate methylated B vitamins.

What this means clinically:

1. Positive MTHFR without elevated homocysteine → monitor, optimize methylated B vitamins, avoid folic acid
2. Elevated homocysteine with MTHFR → treat actively with methylfolate + methylcobalamin
3. Elevated homocysteine without MTHFR → investigate other pathway drivers (B6, renal function, thyroid, medications)

Never use folic acid in MTHFR patients. Unmetabolized folic acid accumulates, may paradoxically block folate receptors, and does not support remethylation. Use 5-MTHF (methylfolate) exclusively.

---

Treatment Protocol

First-Line: B Vitamin Optimization

The primary treatment for elevated homocysteine is correcting B vitamin deficiencies along the affected pathway.

Remethylation support:

• Methylfolate (5-MTHF): 400 mcg–5 mg/day depending on MTHFR status and baseline levels
• Methylcobalamin (B12): 1,000–5,000 mcg/day (sublingual or injection for absorption issues)
• Riboflavin (B2): 100 mg/day (particularly for C677T homozygotes)

Transsulfuration support:

• Pyridoxal-5-phosphate (P5P): 25–100 mg/day (active B6)

Expected response: Homocysteine should drop meaningfully within 6–12 weeks of adequate B vitamin supplementation. Retest at 3 months.

Second-Line: Address Root Causes

If homocysteine doesn't normalize with B vitamin optimization:

1. Check thyroid — hypothyroidism blocks renal clearance; optimize first
2. Check gut absorption — SIBO and gut dysbiosis impair B12 and folate absorption; treat the gut
3. Address medication burden — metformin, PPIs, OCs may require higher B vitamin doses or alternative medications
4. Assess renal function — even mild GFR reduction warrants attention
5. Reduce methionine load — high red meat intake in patients with methylation issues; consider protein cycling

Lifestyle Factors

• Smoking cessation (reduces homocysteine ~2-4 μmol/L)
• Alcohol reduction
• Regular aerobic exercise (mild homocysteine-lowering effect)
• High-folate diet (dark leafy greens, legumes) — though not sufficient alone in MTHFR patients

---

Homocysteine and Cognitive Aging

Homocysteine is not only a cardiovascular marker. Elevated homocysteine is one of the strongest modifiable risk factors for cognitive decline and Alzheimer's disease.

The VITACOG trial demonstrated that B vitamin supplementation reducing homocysteine significantly slowed brain atrophy in individuals with mild cognitive impairment — particularly in those who started with adequate omega-3 fatty acids. The Omega-3 connection matters: DHA appears necessary for B vitamin-mediated protection to take effect.

For cognitive aging patients: Homocysteine <7 μmol/L + DHA >5.7% of RBC fatty acids represents the optimal combination for neurological protection.

---

Documentation in HANS

Homocysteine interpretation in a functional medicine context requires connecting multiple data streams:

• Homocysteine value (with functional vs. conventional range context)
• MTHFR genotype if available
• B12, folate, B6 (P5P) levels
• Relevant medications (metformin, PPIs, OCs)
• Renal function (eGFR, creatinine)
• Thyroid status
• Smoking and alcohol history

HANS generates an integrated interpretation that cross-references all of these automatically, rather than requiring manual chart review before each note. For a patient with elevated homocysteine, the HANS note includes pathway analysis, likely deficiency drivers, treatment protocol with specific supplement forms and doses, and monitoring timeline — formatted for the chart and ready for patient-facing summary.

---

Quick Reference

Homocysteine Level	Interpretation	Action
<7 μmol/L	Optimal	Maintain with adequate B vitamins
7–10 μmol/L	Borderline	Optimize methylated Bs, recheck in 3 months
10–15 μmol/L	Elevated	Active treatment, investigate root causes
15–20 μmol/L	High risk	Urgent treatment, full methylation workup
>20 μmol/L	Hyperhomocysteinemia	Aggressive intervention; rule out rare inborn errors

Bottom line: Homocysteine is cheap to order, fast to interpret, and directly actionable. Every FM patient with cardiovascular risk, cognitive concerns, or known MTHFR variants should have a baseline. The treatment — methylated B vitamins — is safe, inexpensive, and effective.